Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on January 9, 2015. The filing reports corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and related compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased in size from three to four members.
- New Appointment: Thomas A. George was appointed as a director to fill a vacancy.
- Committee Role: Mr. George is designated to chair the Company's audit committee once created.
- Indemnification: The Company entered into indemnification agreements with Mr. George and all current officers and directors.
Compensation and Governance Details
Mr. George's compensation package includes:
- Cash Retainer: $20,000 annually for Board and committee meetings.
- Stock Options (Director): 20,000 options to purchase common stock at fair market value.
- Stock Options (Audit Chair): 20,000 options to purchase common stock at fair market value.
Mr. George brings over 30 years of experience in corporate finance, including roles as CFO at Deckers Brands, Ophthonix, Inc., and Oakley, Inc.
Investor Verification Checklist
- Verify the exact number of outstanding shares to assess the dilution impact of the 40,000 new stock options granted.
- Confirm the timeline for the formal creation of the Audit Committee.
- Review the full text of the Indemnification Agreement (Exhibit 10.1) for specific liability caps or exclusions.
- Check subsequent filings for the Company's financial status, as this 8-K contains no financial performance data.